Physician profile
Matthew Atkinson
NPI 1255493185
$6,921.57
in general payments reported to CMS, 2019-2025
36 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $449 · 2021: $1,180 · 2022: $1,276 · 2023: $901 · 2024: $1,328 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Education: $16.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.51 |
| Education | $16.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,464.09 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,097.91 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $500.89 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $329.72 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $313.14 | 2020-2023 | |
| Celgene Corporation | $233.05 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $229.02 | 2019-2025 | |
| Pfizer INC. | $206.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $202.42 | 2022-2025 | Dupixent |
| Genzyme Corporation | $153.04 | 2022-2025 | |
| Madrigal Pharmaceuticals | $134.88 | 2024-2025 | Resmetirom, Rezdiffra |
| Ironwood Pharmaceuticals, INC | $133.68 | 2020-2023 | Linzess |
| Qol Medical, LLC | $121.19 | 2021-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $99.95 | 2020-2025 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $72.53 | 2024 | Iqirvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $72.09 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $68.47 | 2019-2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $51.93 | 2023-2024 | Voquezna |
| Amgen INC. | $49.05 | 2022-2023 | Avsola, Amjevita |
| Ucb, INC. | $45.79 | 2019 | |
| Allergan, INC. | $42.84 | 2020 | |
| Shire North American Group INC | $38.33 | 2019 | |
| Organon LLC | $29.30 | 2023-2024 | Renflexis |
| Novo Nordisk INC | $29.06 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $28.76 | 2025 | Zenpep |
| Evoke Pharma, INC. | $23.98 | 2021-2022 | |
| Medtronic, INC. | $23.70 | 2022 | |
| Daiichi Sankyo INC. | $16.47 | 2019 | |
| Celltrion USA INC. | $16.15 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $14.90 | 2020 | |
| Vivus LLC | $14.53 | 2023 | Pancreaze |
| Merck Sharp & Dohme LLC | $13.94 | 2021 | |
| Fresenius Kabi USA, LLC | $13.56 | 2023 | Idacio |
| Axonics, INC. | $12.94 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.18 | 2021 | |
| Alfasigma USA, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.